Keyphrases
Signaling Pathway
100%
Phosphorylation
100%
AMP-activated Protein Kinase
100%
De-novo mutations
100%
Hypertrophic Cardiomyopathy
100%
Infantile Onset
100%
PRKAG2 Gene
100%
Phenformin
66%
Protein Kinase Activity
66%
Rapamycin
66%
P70S6K
66%
Hypertrophy
66%
4E-BP1
66%
PRKAG2
66%
PRKAG2 mutation
66%
Overexpression
33%
Age-matched
33%
Neonate
33%
Glycogen
33%
Cellular Stress
33%
HEK293 Cells
33%
Subunit Isoform
33%
Mammalian Target of Rapamycin (mTOR)
33%
Stably Expressing
33%
Target of Rapamycin Signalling
33%
Therapeutic Potential
33%
Primary Fibroblasts
33%
Energy Metabolism
33%
H9c2 Cells
33%
Heterotrimeric
33%
Reduced Sensitivity
33%
Allosteric Activation
33%
5′-AMP-activated Protein Kinase
33%
Ventricular Hypertrophy
33%
Ventricular Pre-excitation
33%
Prenatal Origin
33%
Loss of Response
33%
Cellular Impacts
33%
H9c2 Cardiomyocytes
33%
Medicine and Dentistry
Signal Transduction
100%
Hydroxymethylglutaryl Coenzyme A Reductase Kinase
100%
Hypertrophic Cardiomyopathy
75%
Phenformin
50%
Rapamycin
50%
Induced Mutation
50%
Adenosine Phosphate
25%
Cardiac Muscle Cell
25%
Cellular Stress Response
25%
Cyclic AMP Dependent Protein Kinase
25%
Energy Metabolism
25%
Mechanistic Target of Rapamycin
25%
Neonate
25%
Heart Ventricle Overload
25%
Fibroblast
25%
Biochemistry, Genetics and Molecular Biology
Signal Transduction
100%
PRKAG2
100%
AMP-activated Protein Kinase
80%
Induced Mutation
40%
Enzyme
20%
Wild Type
20%
Protein Kinase A
20%
Adenosine Monophosphate
20%
Isoform
20%
Cardiac Muscle Cell
20%
Cellular Stress Response
20%
Mechanistic Target of Rapamycin
20%
Energy Metabolism
20%
Fibroblast
20%
Pharmacology, Toxicology and Pharmaceutical Science
Hydroxymethylglutaryl Coenzyme A Reductase Kinase
100%
Hypertrophic Cardiomyopathy
75%
Phenformin
50%
Rapamycin
50%
Cyclic AMP Dependent Protein Kinase
25%
Adenosine Phosphate
25%
Mammalian Target of Rapamycin
25%
Heart Ventricle Overload
25%